Tuesday April 11, 9:00 am ET

WOBURN, Mass., April 11 /PRNewswire/ -- AstraZeneca receives top honors at the Strategic Patient Adherence (SPA) Awards. AstraZeneca received awards for the Best Integrated Compliance Program for the Heart Horizon's Treatment Adherence Campaign produced by Simstar, A Rosetta Company, and for the Best Branded Adherence Program for the In Your Corner campaign developed by Wunderman.

The prestigious Strategic Patient Adherence (SPA) Awards co-sponsored by CBI and PharmaVoice were presented at a Gala Dinner hosted by Micromass Communications, Inc. and PharmaCentra as part of the 5th Annual Forum on Patient Compliance, Adherence and Persistency held April 10th in Philadelphia, PA. These awards provided a great platform to pay tribute to outstanding programs in the areas of compliance, adherence and persistency.

Awards were given to pharmaceutical organizations that have been deemed exceptional in their compliance initiatives. Each entry was meticulously reviewed by an esteemed judging panel made up of Grant Corbett, Founder of Behavior Change Solutions, Inc., Dorothy L. Smith, Pharm.D, President and CEO of Consumer Health Information, Jack Barrette, Vice President of Business Development-Healthcare at Yahoo! and Rob Nauman, Principal at BioPharma Advisors.

"The Inaugural SPA awards were a smashing success and the winners proved the value and validity of patient compliance, adherence and persistency programs," said Nkechi J. Enere, Program Manager, Marketing and Medical Affairs, The Center for Business Intelligence.

For information about next year's awards please contact Nkechi J. Enere at 781-939-2403 or Email: nkechi.enere@cbinet.com

About CBI Research, Inc.

CBI is a privately held, world-class conference company that focuses on producing high-level programs for executive decision-makers who face strategic issues in domestic and international markets. CBI has provided information and networking opportunities for thousands of senior-level executives in various industries for nearly ten years. Currently, eighty percent of its events focus on investment opportunities, business strategies, global regulatory issues, operations and applied technologies within the bio/pharmaceutical arena.